The risk of progressive multifocal leukoencephalopathy (PML) associated with prolonged natalizumab use in JCV-seropositive patients might motivate clinicians to switch patients with multiple sclerosis (MS) to fingolimod.(1,2) Many patients with MS taking natalizumab have failed first-line therapies such as interferon-β or glatiramer acetate, and are unlikely to respond to the same therapies after natalizumab.
Centonze, D., Rossi, S., Rinaldi, F., Gallo, P. (2012). Severe relapses under fingolimod treatment prescribed after natalizumab. NEUROLOGY.
Severe relapses under fingolimod treatment prescribed after natalizumab
CENTONZE, DIEGO;
2012-01-01
Abstract
The risk of progressive multifocal leukoencephalopathy (PML) associated with prolonged natalizumab use in JCV-seropositive patients might motivate clinicians to switch patients with multiple sclerosis (MS) to fingolimod.(1,2) Many patients with MS taking natalizumab have failed first-line therapies such as interferon-β or glatiramer acetate, and are unlikely to respond to the same therapies after natalizumab.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
